Put companies on watchlist
MEDICLIN AG
ISIN: DE0006595101
WKN: 659510
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

MEDICLIN AG · ISIN: DE0006595101 · EQS - adhoc news (53 News)
Country: Germany · Primary market: Germany · EQS NID: 2071983
21 January 2025 04:36PM

MEDICLIN raises full-year guidance for the 2024 financial year


EQS-Ad-hoc: MEDICLIN AG / Key word(s): Forecast/Annual Results
MEDICLIN raises full-year guidance for the 2024 financial year

21-Jan-2025 / 16:36 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.


Offenburg, 21 January 2025

MEDICLIN raises full-year guidance for the 2024 financial year

MEDICLIN Aktiengesellschaft (Ticker: MED) announces that it is raising its guidance for the 2024 financial year.

Instead of a Group EBIT* between EUR 33.0 and 39.0 million, MEDICLIN now expects a Group EBIT between EUR 48.0 and 54.0 million. The sales forecast for the Group was raised from -2.0 % to 0.0 % to now 1.0 % to 3.0 %.

The preliminary figures for the fourth quarter and the 2024 financial year will be published on 27 February 2025.

* As defined on the company's website at the following link

Contact for further information:
MEDICLIN Aktiengesellschaft
Okenstraße 27
77652 Offenburg

Ender Gülcan
Head of Investor Relations and Sustainability
Tel.: 0781/488-326
Fax: 0781/488-184
ender.guelcan@mediclin.de
www.mediclin.de
 


End of Inside Information

21-Jan-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: MEDICLIN AG
Okenstraße 27
77652 Offenburg
Germany
Phone: +49 (0)781 488-326
Fax: +49 (0)781 488-184
E-mail: ender.guelcan@mediclin.de
Internet: www.mediclin.de
ISIN: DE0006595101
WKN: 659510
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2071983

 
End of Announcement EQS News Service

2071983  21-Jan-2025 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2071983&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - MEDICLIN AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.